The Newsroom
Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.
Press Release
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors in adults, focusing on breast cancer, head & neck cancer and soft tissue sarcoma.

Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
April 17, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
April 10, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
March 31, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
March 31, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
March 28, 2025
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
March 26, 2025
Discover More
Discover More
Discover More
Press Release
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
March 10, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
February 24, 2025
Discover More
Press Release
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 29, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
January 28, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
January 13, 2025
Discover More
Press Release
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
January 10, 2025
Discover More
Publication
event
RTNova
RTNova
NeuroNova
Supernova
Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy
November 13, 2024
Discover More
Discover More
Publication
event
NeuroNova (NNV)
NeuroNova (NNV)
NeuroNova
Supernova
Phase 1 Study of Multiple Intracerebral Doses of a Neural Stem Cell-based Oncolytic Virotherapy for Treatment of Recurrent High-grade Gliomas
June 1, 2024
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova
Non-Clinical Evidence Supporting the Upcoming CLD-201 Clinical Trial: Cell-Based Oncolytic Virotherapy for Multiple Solid Tumors
June 1, 2024
Discover More
Discover More
Publication
event
RTNova
RTNova
NeuroNova
Supernova
Transforming Tumor Immune Microenvironments with a Novel Systemic Enveloped Oncolytic Virotherapy Targeting All Tumor Sites
June 1, 2024
Discover More
Discover More
Publication
event
NeuroNova & SuperNova
NeuroNova & SuperNova
NeuroNova
Supernova
Stem Cell Platforms for Enhanced Oncolytic Virotherapy
April 16, 2024
Discover More
Discover More
Publication
event
NeuroNova & SuperNova
NeuroNova & SuperNova
NeuroNova
Supernova
Deciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem Cells
April 9, 2024
Discover More
Discover More
Media
Scientific Advisory Board Member Interview - Santosh Kesari, M.D./Ph.D.
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - Bernard Fox, Ph.D.
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - W.K. Alfred Yung, M.D.
February 3, 2024
Discover More
Media
Scientific Advisory Board Member Interview - Ashok Srivastava, M.D./Ph.D.
February 3, 2024
Discover More
Media
Big Biz TV - Stephen Thesing
December 4, 2023
Discover More
Media
Big Biz TV - Allan Camaisa
December 4, 2023
Discover More
In The News
Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
October 9, 2023
Discover More
Discover More
In The News
Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
October 9, 2023
Discover More
Discover More